Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05153239




Registration number
NCT05153239
Ethics application status
Date submitted
29/11/2021
Date registered
10/12/2021
Date last updated
2/08/2024

Titles & IDs
Public title
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
Scientific title
A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination With Irinotecan Versus Investigator's Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer Patients (LAGOON Trial)
Secondary ID [1] 0 0
PM1183-C-008-21
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Relapsed Small Cell Lung Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Irinotecan
Treatment: Drugs - Lurbinectedin
Treatment: Drugs - Irinotecan
Treatment: Drugs - Topotecan
Treatment: Drugs - Lurbinectedin

Experimental: Lurbinectedin - Patients will consecutively receive lurbinectedin on Day 1 q3wk (every three weeks = one treatment cycle)

Experimental: Lurbinectedin plus Irinotecan - Patients will consecutively receive the following q3wk (every three weeks = one treatment cycle):

* Irinotecan (Day 1 and Day 8)
* Lurbinectedin (Day 1)

Active comparator: Control arm - Best Investigator's choice prior to randomization between:

* Irinotecan on Day 1 q3wk
* Topotecan on Days 1-5 q3wk


Treatment: Drugs: Irinotecan
Irinotecan 75 mg/m² intravenously Days 1 \& 8 q3wk

Treatment: Drugs: Lurbinectedin
Lurbinectedin 3.2 mg/m² will be administered intravenously on Day 1 q3wk

Treatment: Drugs: Irinotecan
For patients aged \<70 years: irinotecan 350 mg/m² intravenously Day 1 q3wk For patients aged =70 years: irinotecan 300 mg/m² intravenously Day 1 q3wk

Treatment: Drugs: Topotecan
Topotecan 2.3 mg/m² oral or 1.5 mg/m² intravenously Days 1-5 q3wk

Treatment: Drugs: Lurbinectedin
Lurbinectedin 2.0 mg/m² will be administered intravenously on Day 1 q3wk
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall survival
Timepoint [1] 0 0
From the date of randomization to the date of death or last contact, up to 39 months
Secondary outcome [1] 0 0
Progression-free survival by IRC (Independent Review Committee)
Timepoint [1] 0 0
From the date of randomization to the date of progressive disease, death or last tumor assessment or further anticancer treatment, up to 39 months
Secondary outcome [2] 0 0
Progression-free survival by IA (Investigator Assessment)
Timepoint [2] 0 0
From the date of randomization to the date of progressive disease, death or last tumor assessment or further anticancer treatment, up to 39 months
Secondary outcome [3] 0 0
Overall response rate by IRC
Timepoint [3] 0 0
From the date of randomization to the date of death or last contact, up to 39 months
Secondary outcome [4] 0 0
Overall response rate by IA
Timepoint [4] 0 0
From the date of randomization to the date of death or last contact, up to 39 months
Secondary outcome [5] 0 0
Overall survival rate at 12 months
Timepoint [5] 0 0
At 12 months
Secondary outcome [6] 0 0
Overall survival rate at 24 months
Timepoint [6] 0 0
At 24 months
Secondary outcome [7] 0 0
Progression-free survival rate at 6 months by IRC
Timepoint [7] 0 0
At 6 months
Secondary outcome [8] 0 0
Progression-free survival rate at 6 months by IA
Timepoint [8] 0 0
At 6 months
Secondary outcome [9] 0 0
Progression-free survival rate at 12 months by IRC
Timepoint [9] 0 0
At 12 months
Secondary outcome [10] 0 0
Progression-free survival rate at 12 months by IA
Timepoint [10] 0 0
At 12 months
Secondary outcome [11] 0 0
Duration of response by IRC
Timepoint [11] 0 0
From the date of first documentation of complete or partial response to the date of documented progression disease, death or last contact, up to 39 months
Secondary outcome [12] 0 0
Duration of response by IA
Timepoint [12] 0 0
From the date of first documentation of complete or partial response to the date of documented progression disease, death or last contact, up to 39 months
Secondary outcome [13] 0 0
Patient-reported outcomes
Timepoint [13] 0 0
At baseline and every six weeks (± one week) until end of treatment, up to 39 months

Eligibility
Key inclusion criteria
1. Voluntary written informed consent of the patient obtained before any study-specific procedure
2. Age=18 years
3. Histologically or cytologically confirmed diagnosis of SCLC.
4. One prior line of platinum-containing chemotherapy with/without anti-PD-1 or anti-PD-L1 (Note: at least 70% of patients included in the study have to be pretreated with anti-PD-1 or anti-PD-L1)
5. Chemotherapy-free interval (CTFI, time from the last dose of first-line platinum-containing chemotherapy to the occurrence of progressive disease) = 30 days (independent of the immunotherapy maintenance, if applicable)
6. Patients with history of Central Nervous System (CNS) metastases can participate provided they are pretreated and radiologically stable (i.e., without evidence of progression) for at least 4 weeks by repeated imaging (note: repeated imaging should be performed during study screening), asymptomatic, and without requirement of steroid treatment for at least 7 days before the first dose of study treatment
7. Eastern Cooperative Oncology Group (ECOG) PS = 2
8. Adequate hematological, renal, metabolic and hepatic function:

1. Hemoglobin = 9.0 g/dL [patients may have received prior red blood cell (RBC) transfusion, if clinically indicated]; absolute neutrophil count (ANC) = 2.0 x 10^9/L, and platelet count = 100 x 10^9/L.
2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 3.0 x upper limit of normal (ULN).
3. Total bilirubin = 1.5 x ULN or direct bilirubin = ULN.
4. Albumin = 3.0 g/dL.
5. Calculated creatinine clearance (CrCL) = 30 mL/min (using Cockcroft and Gault's formula).
9. At least three weeks since last prior antineoplastic treatment and recovery to grade = 1 from any adverse event (AE) related to previous anticancer treatment (excluding sensory neuropathy, anemia, asthenia and alopecia, all grade = 2) according to the National Cancer InstituteCommon Terminology Criteria for Adverse Events (NCICTCAE) v.5.
10. Prior radiotherapy (RT): At least two weeks since completion of prophylactic cranial irradiation (PCI), and to any other site not previously specified.
11. Evidence of non-childbearing status for women of childbearing potential (WOCBP). WOCBP must agree to use a highly effective contraceptive measure up to seven months after treatment discontinuation. Fertile male patients with WOCBP partners should use condoms during treatment and for four months following the last investigational medicinal product (IMP) dose.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Platinum-naïve patients or patients pretreated with more than one prior chemotherapy regimen (including patients re-challenged with same initial regimen).
2. Prior treatment with lurbinectedin, trabectedin, PM14, or topoisomerase I inhibitors (irinotecan, topotecan, etc.).
3. Active or untreated CNS metastases and/or carcinomatous meningitis.
4. Patients with limited-stage disease who are candidates for local or regional therapy, including PCI, thoracic RT or both, must have been offered that option and completed treatment or refused it prior to randomization.
5. Concomitant diseases/conditions:

1. History or presence of unstable angina, myocardial infarction, congestive heart failure, or clinically significant valvular heart disease within last year.
2. Symptomatic arrhythmia or any uncontrolled arrhythmia requiring ongoing treatment.
3. Ongoing chronic alcohol consumption or cirrhosis with Child-Pugh score B or C.
4. Known Gilbert's disease.
5. Active uncontrolled infection. Serious non-healing wound, ulcer or bone fracture. Presence of external drainages.
6. Ongoing, treatment-requiring, non-neoplastic chronic liver disease of any origin. For Hepatitis B, this includes positive tests for both Hepatitis B surface antigen (HBsAg) and quantitative Hepatitis B polymerase chain reaction (PCR). For Hepatitis C, this includes positive tests for both Hepatitis C antibody and quantitative Hepatitis C PCR. Subjects taking hepatitis related antiviral therapy within six months prior to the first dose of study drugs will also be excluded.
7. Intermittent or continuous oxygen requirement within two weeks prior to randomization. Patients with confirmed or suspected diagnosis of diffuse interstitial lung disease or pulmonary fibrosis.
8. Patients with a second invasive malignancy treated with chemotherapy and/or RT. Patients with a previous malignancy that was completely resected with curative intention three or more years prior to randomization, except treated in situ carcinoma of the cervix, basal or squamous cell skin carcinoma, and in situ transitional cell bladder carcinoma and who has been continuously in remission since then will be permitted.
9. Limitation of the patient's ability to comply with the treatment or to follow the protocol.
10. Documented or suspected invasive fungal infections requiring systemic treatment within 12 weeks of randomization.
11. Known human immunodeficiency virus (HIV) infection.
12. Any past or present chronic inflammatory colon and/or liver disease, past intestinal obstruction, pseudo or subocclusion or paralysis.
13. Evident symptomatic pleural or cardiac effusion rapidly increasing and/or necessitating prompt local treatment within seven days.
14. Any other major illness that, in the Investigator's judgment, will substantially increase the risk associated with the patient's participation in this study (e.g.; COVID-19 disease).
6. RT in more than 35% of the bone marrow.
7. History of previous bone marrow and/or stem cell transplantation and allogenic transplant.
8. Patient has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of inactivated vaccines is allowed.
9. Impending need for RT (e.g., painful bone metastasis and/or risk of spinal cord compression).
10. History of allergy or hypersensitivity to any of the study drugs or any of their excipients.
11. Women who are pregnant or breast feeding and fertile patients (men and women) who are not able to use a highly effective method of contraception

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
22/07/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/04/2026
Actual
Sample size
Target
705
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
The Chris Obrien Lifehouse - Camperdown
Recruitment hospital [2] 0 0
BRICC - Ballarat Health Services - Ballarat Central
Recruitment hospital [3] 0 0
Box Hill Hospital Eastern Health Clinical School - Box Hill
Recruitment hospital [4] 0 0
Northern Beaches Hospital - Frenchs Forest
Recruitment hospital [5] 0 0
Gosford Hospital GH - Central Coast Cancer Centre - Gosford
Recruitment hospital [6] 0 0
Austin Hospital- Medical Oncology Unit - Heidelberg
Recruitment hospital [7] 0 0
St John of God Murdoch Hospital - Murdoch
Recruitment hospital [8] 0 0
Cancer Care Wollongong - Wollongong
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
3350 - Ballarat Central
Recruitment postcode(s) [3] 0 0
3128 - Box Hill
Recruitment postcode(s) [4] 0 0
NSW 2086 - Frenchs Forest
Recruitment postcode(s) [5] 0 0
2250 - Gosford
Recruitment postcode(s) [6] 0 0
VIC 3084 - Heidelberg
Recruitment postcode(s) [7] 0 0
WA 6150 - Murdoch
Recruitment postcode(s) [8] 0 0
NSW 2500 - Wollongong
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Kentucky
Country [6] 0 0
United States of America
State/province [6] 0 0
Massachusetts
Country [7] 0 0
United States of America
State/province [7] 0 0
Nebraska
Country [8] 0 0
United States of America
State/province [8] 0 0
North Carolina
Country [9] 0 0
United States of America
State/province [9] 0 0
Utah
Country [10] 0 0
United States of America
State/province [10] 0 0
Washington
Country [11] 0 0
United States of America
State/province [11] 0 0
Wisconsin
Country [12] 0 0
Austria
State/province [12] 0 0
Salzburg
Country [13] 0 0
Austria
State/province [13] 0 0
Vienna
Country [14] 0 0
Belgium
State/province [14] 0 0
Antwerp
Country [15] 0 0
Belgium
State/province [15] 0 0
Brasschaat
Country [16] 0 0
Belgium
State/province [16] 0 0
Charleroi
Country [17] 0 0
Belgium
State/province [17] 0 0
Liège
Country [18] 0 0
Belgium
State/province [18] 0 0
Mechelen
Country [19] 0 0
Belgium
State/province [19] 0 0
Mons
Country [20] 0 0
Brazil
State/province [20] 0 0
Parana
Country [21] 0 0
Brazil
State/province [21] 0 0
Porto Alegre
Country [22] 0 0
Brazil
State/province [22] 0 0
Salvador
Country [23] 0 0
Brazil
State/province [23] 0 0
Barretos
Country [24] 0 0
Brazil
State/province [24] 0 0
Ijuí
Country [25] 0 0
Brazil
State/province [25] 0 0
Rio De Janeiro
Country [26] 0 0
Bulgaria
State/province [26] 0 0
Panagyurishte
Country [27] 0 0
Bulgaria
State/province [27] 0 0
Plovdiv
Country [28] 0 0
Bulgaria
State/province [28] 0 0
Sofia
Country [29] 0 0
Canada
State/province [29] 0 0
Ontario
Country [30] 0 0
Canada
State/province [30] 0 0
Quebec
Country [31] 0 0
Canada
State/province [31] 0 0
Montréal
Country [32] 0 0
Canada
State/province [32] 0 0
Toronto
Country [33] 0 0
Chile
State/province [33] 0 0
Araucania
Country [34] 0 0
Chile
State/province [34] 0 0
Los Ríos
Country [35] 0 0
Chile
State/province [35] 0 0
Santiago de Chile
Country [36] 0 0
Denmark
State/province [36] 0 0
Aalborg
Country [37] 0 0
Denmark
State/province [37] 0 0
Næstved
Country [38] 0 0
Denmark
State/province [38] 0 0
Sønderborg
Country [39] 0 0
Denmark
State/province [39] 0 0
Vejle
Country [40] 0 0
France
State/province [40] 0 0
Besancon
Country [41] 0 0
France
State/province [41] 0 0
Boulogne-Billancourt
Country [42] 0 0
France
State/province [42] 0 0
Brest
Country [43] 0 0
France
State/province [43] 0 0
Caen
Country [44] 0 0
France
State/province [44] 0 0
Créteil
Country [45] 0 0
France
State/province [45] 0 0
Limoges
Country [46] 0 0
France
State/province [46] 0 0
Nantes
Country [47] 0 0
France
State/province [47] 0 0
Paris
Country [48] 0 0
France
State/province [48] 0 0
Reims
Country [49] 0 0
France
State/province [49] 0 0
Strasbourg
Country [50] 0 0
France
State/province [50] 0 0
Suresnes
Country [51] 0 0
France
State/province [51] 0 0
Villejuif
Country [52] 0 0
Georgia
State/province [52] 0 0
Batumi
Country [53] 0 0
Georgia
State/province [53] 0 0
Tbilisi
Country [54] 0 0
Germany
State/province [54] 0 0
Schleswig Holstein
Country [55] 0 0
Germany
State/province [55] 0 0
Bad Berka
Country [56] 0 0
Germany
State/province [56] 0 0
Berlin
Country [57] 0 0
Germany
State/province [57] 0 0
Bremen
Country [58] 0 0
Germany
State/province [58] 0 0
Duisburg
Country [59] 0 0
Germany
State/province [59] 0 0
Esslingen
Country [60] 0 0
Germany
State/province [60] 0 0
Freiburg
Country [61] 0 0
Germany
State/province [61] 0 0
Gauting
Country [62] 0 0
Germany
State/province [62] 0 0
Halle (saale)
Country [63] 0 0
Germany
State/province [63] 0 0
Halle
Country [64] 0 0
Germany
State/province [64] 0 0
Heidelberg
Country [65] 0 0
Germany
State/province [65] 0 0
Karlsruhe
Country [66] 0 0
Germany
State/province [66] 0 0
Kassel
Country [67] 0 0
Germany
State/province [67] 0 0
Löwenstein
Country [68] 0 0
Germany
State/province [68] 0 0
Mannheim
Country [69] 0 0
Germany
State/province [69] 0 0
München
Country [70] 0 0
Germany
State/province [70] 0 0
Offenbach
Country [71] 0 0
Hungary
State/province [71] 0 0
Debrecen
Country [72] 0 0
Hungary
State/province [72] 0 0
Farkasgyepu
Country [73] 0 0
Hungary
State/province [73] 0 0
Kecskemét
Country [74] 0 0
Hungary
State/province [74] 0 0
Szolnok
Country [75] 0 0
Hungary
State/province [75] 0 0
Törökbálint
Country [76] 0 0
Israel
State/province [76] 0 0
Haifa
Country [77] 0 0
Israel
State/province [77] 0 0
Jerusalem
Country [78] 0 0
Israel
State/province [78] 0 0
Petah tikva
Country [79] 0 0
Israel
State/province [79] 0 0
Ramat Gan
Country [80] 0 0
Israel
State/province [80] 0 0
Tel Aviv
Country [81] 0 0
Italy
State/province [81] 0 0
Alessandria
Country [82] 0 0
Italy
State/province [82] 0 0
Ancona
Country [83] 0 0
Italy
State/province [83] 0 0
Aviano
Country [84] 0 0
Italy
State/province [84] 0 0
Bologna
Country [85] 0 0
Italy
State/province [85] 0 0
Catania
Country [86] 0 0
Italy
State/province [86] 0 0
Cuneo
Country [87] 0 0
Italy
State/province [87] 0 0
Florence
Country [88] 0 0
Italy
State/province [88] 0 0
Genova
Country [89] 0 0
Italy
State/province [89] 0 0
Milan
Country [90] 0 0
Italy
State/province [90] 0 0
Napoli
Country [91] 0 0
Italy
State/province [91] 0 0
Novara
Country [92] 0 0
Italy
State/province [92] 0 0
Orbassano
Country [93] 0 0
Italy
State/province [93] 0 0
Padova
Country [94] 0 0
Italy
State/province [94] 0 0
Piacenza
Country [95] 0 0
Italy
State/province [95] 0 0
Rionero In Vulture
Country [96] 0 0
Italy
State/province [96] 0 0
Roma
Country [97] 0 0
Italy
State/province [97] 0 0
Siena
Country [98] 0 0
Italy
State/province [98] 0 0
Sondrio
Country [99] 0 0
Italy
State/province [99] 0 0
Varese
Country [100] 0 0
Japan
State/province [100] 0 0
Aomori
Country [101] 0 0
Japan
State/province [101] 0 0
Fukuoka
Country [102] 0 0
Japan
State/province [102] 0 0
Hyogo
Country [103] 0 0
Japan
State/province [103] 0 0
Ishikawa
Country [104] 0 0
Japan
State/province [104] 0 0
Miyagi
Country [105] 0 0
Japan
State/province [105] 0 0
Okayama
Country [106] 0 0
Japan
State/province [106] 0 0
Osaka-Fu
Country [107] 0 0
Japan
State/province [107] 0 0
Osaka
Country [108] 0 0
Japan
State/province [108] 0 0
Tokyo
Country [109] 0 0
Korea, Republic of
State/province [109] 0 0
Cheongju-si
Country [110] 0 0
Korea, Republic of
State/province [110] 0 0
Gyeonggi-do
Country [111] 0 0
Korea, Republic of
State/province [111] 0 0
Incheon
Country [112] 0 0
Korea, Republic of
State/province [112] 0 0
Seoul
Country [113] 0 0
Poland
State/province [113] 0 0
Bialystok
Country [114] 0 0
Poland
State/province [114] 0 0
Gdynia
Country [115] 0 0
Poland
State/province [115] 0 0
Lublin
Country [116] 0 0
Poland
State/province [116] 0 0
Prabuty
Country [117] 0 0
Poland
State/province [117] 0 0
Rzeszów
Country [118] 0 0
Poland
State/province [118] 0 0
Tomaszów Mazowiecki
Country [119] 0 0
Poland
State/province [119] 0 0
Lódz
Country [120] 0 0
Romania
State/province [120] 0 0
Baia Mare
Country [121] 0 0
Romania
State/province [121] 0 0
Cluj-Napoca
Country [122] 0 0
Romania
State/province [122] 0 0
Craiova
Country [123] 0 0
Romania
State/province [123] 0 0
Ovidiu
Country [124] 0 0
Romania
State/province [124] 0 0
Timisoara
Country [125] 0 0
Spain
State/province [125] 0 0
Barcelona
Country [126] 0 0
Spain
State/province [126] 0 0
Cantabria
Country [127] 0 0
Spain
State/province [127] 0 0
Gran Canaria
Country [128] 0 0
Spain
State/province [128] 0 0
Navarra
Country [129] 0 0
Spain
State/province [129] 0 0
Pontevedra
Country [130] 0 0
Spain
State/province [130] 0 0
A Coruña
Country [131] 0 0
Spain
State/province [131] 0 0
Córdoba
Country [132] 0 0
Spain
State/province [132] 0 0
Lugo
Country [133] 0 0
Spain
State/province [133] 0 0
Madrid
Country [134] 0 0
Spain
State/province [134] 0 0
Málaga
Country [135] 0 0
Spain
State/province [135] 0 0
Sevilla
Country [136] 0 0
Spain
State/province [136] 0 0
Valencia
Country [137] 0 0
Spain
State/province [137] 0 0
Valladolid
Country [138] 0 0
Spain
State/province [138] 0 0
Zaragoza
Country [139] 0 0
Switzerland
State/province [139] 0 0
Basel
Country [140] 0 0
Switzerland
State/province [140] 0 0
Bellinzona
Country [141] 0 0
Switzerland
State/province [141] 0 0
Frauenfeld
Country [142] 0 0
Switzerland
State/province [142] 0 0
Lausanne
Country [143] 0 0
Switzerland
State/province [143] 0 0
Liestal
Country [144] 0 0
Switzerland
State/province [144] 0 0
Münsterlingen
Country [145] 0 0
Switzerland
State/province [145] 0 0
Villars-sur-Glâne
Country [146] 0 0
Taiwan
State/province [146] 0 0
Chiayi
Country [147] 0 0
Taiwan
State/province [147] 0 0
Chang Hua
Country [148] 0 0
Taiwan
State/province [148] 0 0
Kaohsiung
Country [149] 0 0
Taiwan
State/province [149] 0 0
Taipei
Country [150] 0 0
Taiwan
State/province [150] 0 0
Taoyuan
Country [151] 0 0
Turkey
State/province [151] 0 0
Adana
Country [152] 0 0
Turkey
State/province [152] 0 0
Ankara
Country [153] 0 0
Turkey
State/province [153] 0 0
Istambul
Country [154] 0 0
Turkey
State/province [154] 0 0
Kocaeli
Country [155] 0 0
United Kingdom
State/province [155] 0 0
Belfast
Country [156] 0 0
United Kingdom
State/province [156] 0 0
Harlow
Country [157] 0 0
United Kingdom
State/province [157] 0 0
London
Country [158] 0 0
United Kingdom
State/province [158] 0 0
Manchester
Country [159] 0 0
United Kingdom
State/province [159] 0 0
Nottingham
Country [160] 0 0
United Kingdom
State/province [160] 0 0
Wirral
Country [161] 0 0
United Kingdom
State/province [161] 0 0
Wolverhampton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
PharmaMar
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
José Antonio Lopez-Vilariño, MD
Address 0 0
Country 0 0
Phone 0 0
0034 91 823 4564
Fax 0 0
Email 0 0
jalopez-vilarino@pharmamar.com
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT05153239